Shilpa Medicare Limited announced that the company has received approval from the Office of the Directorate of Ayurveda and Unani Services (division of the Ministry of Aayush) for the manufacture and sale of Oral Mucositis Spray a treatment option made available for the first time in India under the brand name ORAAL. "The composition of ORAAL is protected by a granted patent in India until November 2033." Shilpa will commercialize the product under the brand name ORAal which will be launched immediately. ORAAL, a substantial advancement in Oral Mucositis management, has been accepted and approved by the Indian Dental Association (IDA).

With the commitment towards 'Thoughtful Innovation for Powerful Outcomes', Shilpa's ORAAL is indicated for the treatment of all grades of Mucositis. ORAAL is backed by required scientific proof for the treatment of Oral Mucositis. The launch of ORAAL, an Oral spray with a naturally derived formulation in India will offer great benefits in terms of flexibility and patient convenience for use in any condition, and is advantageous in reducing the chemical-based mouth rinse usage and also delivering appropriate dosing to the patient without any side effects.

A dosage of 4-5 sprays, 2-3 times a day can maintain Oral hydration and work towards healing Oral Mucositis from the first spray itself and starts showing effects within 20 minutes. Shilpa's formula, enriched with Curcuma Longa, Honey, Glycerin, and Purified Water, has been carefully crafted to provide soothing relief in a convenient spray form. Curcuma Longa: Nature's Gift - Renowned for its anti-inflammatory properties.

Honey: Sweet Nectar - Known for its healing and antibacterial benefits. Glycerin & Purified Water: Hydration - Keeps mouth comfortable and moist. ORAAL forms a protective barrier, aiding in the healing process of oral mucositis.